Immunotherapy News and Research

Latest Immunotherapy News and Research

Discovery of progenitor exhausted T cells offers hope for cancer patients

Tumor immunotherapy leverages the body's immune system to target and eradicate cancer cells, offering a crucial treatment for patients unresponsive to surgery or conventional therapies. Despite its potential, the effectiveness of immunotherapy is often hindered by T cell exhaustion within the tumor microenvironment, leading to diminished immune response and tumor progression. Based on these challenges, exploring the role of progenitor exhausted T cells (Tpex) in overcoming immune resistance is essential for advancing immunotherapeutic strategies and improving clinical outcomes.

8 Aug 2024

Study links renalase-1 and T-cell receptor interaction to increased melanoma survival

A new research paper was published in Oncotarget's Volume 15 on August 5, 2024, entitled, "Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival."

8 Aug 2024

Gene activity can predict severe side effects from melanoma treatment

An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a new study shows.

8 Aug 2024

Zebrafish model reveals how BCG vaccine triggers immune response in bladder cancer

Using zebrafish "Avatars", an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD student at the lab now working at the Universidad de las Américas in Quito, Ecuador – and colleagues studied the initial steps of the Bacillus Calmette-Guérin (BCG) vaccine's action on bladder cancer cells.

8 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

Amyloid immunotherapy for early Alzheimer's: Promising but fraught with challenges

Researchers highlighted the complexities of using amyloid immunotherapy for early Alzheimer's disease, discussing its clinical benefits, challenges, and broader health implications. Despite some positive results, concerns over adverse effects, trial biases, and cost hinder widespread adoption.

7 Aug 2024

Discovery of Tr1 cells as a barrier to cancer immunotherapy offers new hope for treatment

Immunobiologists Robert Schreiber, PhD, (left) and Hussein Sultan, PhD, of Washington University School of Medicine in St. Louis, found that a subset of immune cells that normally puts the brakes on the immune system to prevent it from attacking the body's healthy cells inadvertently also dampens cancer immunotherapy.

7 Aug 2024

METRNL protein identified as key player in cancer progression

A protein called Meteorin-like (METRNL) in the tumor microenvironment saps energy from T cells, thereby severely limiting their ability to fight cancer, according to new research directed by investigators at the Johns Hopkins University School of Medicine and the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. Finding ways to block the effects of METRNL signaling on tumor-infiltrating T cells may allow these immune cells to regain the energy necessary to eliminate tumors.

7 Aug 2024

Researchers uncover immune system barrier to cancer treatment

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments.

7 Aug 2024

The interplay of liver cancer stem cells and immune cells in tumor microenvironment

The complex dynamics between liver cancer stem cells (CSCs) and immune cells within the tumor microenvironment (TME) are central to the progression of liver cancer. These interactions are critical in creating an immunosuppressive setting that significantly impacts the response to immunotherapy. Liver CSCs, responsible for tumor initiation, metastasis, therapeutic resistance, and recurrence, exhibit heterogeneity and are characterized by various surface markers that contribute to their stemness and metastatic potential.

7 Aug 2024

FDA approves vorasidenib for Grade 2 gliomas with IDH mutations

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.

6 Aug 2024

Histopathologic features of immune checkpoint inhibitor-induced myocarditis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Recent advancements in immunotherapy have substantially improved overall survival and quality of life among patients with cancer.

6 Aug 2024

Cambridge experts question efficacy and practicality of new amyloid immunotherapy drugs

Cambridge researchers have cast doubt on whether new amyloid immunotherapy drugs will have the desired effect of significantly reducing the impact of Alzheimer's disease.

6 Aug 2024

Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomes

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

6 Aug 2024

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells.

5 Aug 2024

Immunotherapy significantly improves survival rates for advanced lung cancer patients, study finds

Since the first immunotherapy drug to boost the body's immune response against advanced lung cancer was introduced in the United States in 2015, survival rates of patients with the disease have improved significantly.

5 Aug 2024

UCLA launches groundbreaking clinical trial for vaccine targeting aggressive pediatric brain cancer

In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that is typically found in adolescents and young adults.

5 Aug 2024

New nanoparticle-based immunotherapy delays hormone therapy resistance in prostate cancer

A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer.

5 Aug 2024

Breakthrough study identifies mechanisms behind glucocorticoid resistance in pediatric B-ALL

Josep Carreras Leukaemia Research Institute B-ALL is the most common paediatric cancer and, over the years and thanks to a very effective treatment based on glucocorticoids, its 5-year survival rates have reached 85% and beyond.

5 Aug 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024

Immunotherapy News and Research

Latest Immunotherapy News and Research

Discovery of progenitor exhausted T cells offers hope for cancer patients

Study links renalase-1 and T-cell receptor interaction to increased melanoma survival

Gene activity can predict severe side effects from melanoma treatment

Zebrafish model reveals how BCG vaccine triggers immune response in bladder cancer

Review of fasting-mimicking diets in cancer treatment

Amyloid immunotherapy for early Alzheimer's: Promising but fraught with challenges

Discovery of Tr1 cells as a barrier to cancer immunotherapy offers new hope for treatment

METRNL protein identified as key player in cancer progression

Researchers uncover immune system barrier to cancer treatment

The interplay of liver cancer stem cells and immune cells in tumor microenvironment

FDA approves vorasidenib for Grade 2 gliomas with IDH mutations

Histopathologic features of immune checkpoint inhibitor-induced myocarditis

Cambridge experts question efficacy and practicality of new amyloid immunotherapy drugs

Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomes

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

Immunotherapy significantly improves survival rates for advanced lung cancer patients, study finds

UCLA launches groundbreaking clinical trial for vaccine targeting aggressive pediatric brain cancer

New nanoparticle-based immunotherapy delays hormone therapy resistance in prostate cancer

Breakthrough study identifies mechanisms behind glucocorticoid resistance in pediatric B-ALL

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in